Current Medical Research and Opinion · 2009 · 46 citations · 23 references
MedicineOncologyPharmacoeconomicsChemotherapyCost-effectiveness AnalysisMedical OncologyAdverse Effects Of ChemotherapyChemotherapy In Hematologic MalignanciesFebrile Neutropenia ManagementNeutropenia ManagementCancer Cost BurdenDirect CostsDirect Treatment CostsFebrile Neutropenia TreatmentG-csf TherapyHealthcare Resource UtilizationOutcome MeasuresRetrospective Cost Analysis
BACKGROUND: Febrile neutropenia (FN) is associated with disruption of planned chemotherapy and increased management costs. However, the economic impact of FN in Spanish clinical practice has not been documented hitherto. RESEARCH DESIGN AND METHODS: A multicenter, retrospective chart review of adults with breast or lung cancer or non-Hodgkin's lymphoma (NHL) who had > or = 1 FN episode during chemotherapy. Resource use, direct costs, and FN effect on planned chemotherapy were assessed. MAIN OUTCOME MEASURES: 238 episodes of FN were analyzed in 194 patients. The mean + or - SD length of FN-related hospitalization was 8.7 + or - 6.9 days (median [p(25)-p(75)] = 7 [5-11] days). At least one transfusion was needed in 77 (32.3%) FN episodes, blood tests were done in 233 (97.9%) and blood cultures in 207 (87.0%). Antibiotics were used in all episodes (100%), other drugs in 186 (78.2%) episodes and the granulocyte colony-stimulating factor (G-CSF) in 161 (67.7%) episodes. The distribution of costs per episode of FN were: hospitalization 79%, antibiotics 10%, G-CSF 5%, complementary tests 4%; other drugs 1%, blood transfusions 1%. The estimated mean (95% CI) cost per FN episode was euro3841 (95% CI: euro3476-4206). FN management was costlier in NHL patients euro4514 (95% CI: euro3805-5223) than in breast or lung cancer patients (euro3519 [95% CI: euro2976-4061] and euro3311 [95% CI: euro2817-3805] respectively) (P < 0.05 both comparisons). Planned chemotherapy was disrupted in 139 (58.4%) episodes (dose reductions in 75 [34.9%], dose delays in 60 [28.0%] and withdrawal in 33 [14.7%]). CONCLUSIONS: FN substantially affects healthcare resource use and costs in breast cancer, lung cancer and, NHL. In this study, hospitalization and antibiotics were the main drivers of cost. A limitation of the analysis was that it did not include the indirect costs associated with FN episodes.
23
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
Nicole M. Kuderer, David C. Dale, Jeffrey Crawford et al. · Cancer · 2006 · 1.2K citations · Full text
Cancer principles and practice of oncology
Michael J. Kerin · Surgical Oncology · 1997 · 745 citations
Medicine, Oncology, Oncology Nursing +12
Frankie A. Holmes, Joyce O’Shaughnessy, S. Vukelja et al. · Journal of Clinical Oncology · 2002 · 517 citations
Medicine, Oncology, Pharmacology +17
Charles L. Vogel, Marek Z. Wojtukiewicz, Robert R. Carroll et al. · Journal of Clinical Oncology · 2005 · 481 citations · Full text
Medicine, Oncology, Pharmacology +16